Abiopharma

🔍 CASHIN RICHARD M JR (Executive)

Company: AdaptHealth Corp. (AHCO)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 820,528 shares of Common Stock at $9.7287 per share (Direct)
  Date: 2026-03-10 | Code: P | equity_swap_involved: false | shares_owned_after: 14,638,708.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 536,827 shares of Common Stock at $9.7281 per share (Direct)
  Date: 2026-03-11 | Code: P | equity_swap_involved: false | shares_owned_after: 15,175,535.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Acquired 689,336 shares of Common Stock at $9.7299 per share (Direct)
  Date: 2026-03-12 | Code: P | equity_swap_involved: false | shares_owned_after: 15,864,871.00 | transaction_form_type: 4 | Footnotes: F5, F2

Footnotes:

• F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.58 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F2: These securities are held directly by OEP AHCO Investment Holdings, VI LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").
• F3: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.
• F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.64 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F5: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.55 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• REMARKS: EDGAR filing codes for Investor, the Parallel Funds, OEP VII GP, OEP VII GP LLC (collectively, the "OEP Entities") were not accessible at the time of this filing but, as direct and indirect holders of the reported securities, are intended and deemed to be included as reporting persons on this Form 4. When such EDGAR filing codes are received from the Securities and Exchange Commission, this Form 4 will be amended to reflect the OEP Entities as reporting persons.